Inflammatix secures $57M for its breakthrough infectious disease test, pending FDA review, aiming to revolutionize sepsis ...

University College London's new wearable brain imaging device unveils how babies' brains react in natural settings, shedding ...

In a recent development, the Scottish Medicines Consortium has approved Tecvayli (teclistamab) for patients with RRMM, making Scotland the first UK nation to authorize this innovative bispecific ...

Zepp Health Corporation, a leading innovator in smart wearables, has teamed up with wellness app Wild.AI to introduce advanced women’s health features to Amazfit smartwatches. Starting with the ...

Vita Animal Health has introduced an enhanced version of its cardiac health supplement, Omnicardio Plus, specifically designed for cats and dogs. This new formula features astaxanthin, a potent ...

NHS dental services on the Isle of Wight have reached a breaking point as yet another practice faces closure due to serious staff shortages. This is the sixth closure in the past 18 months, raising ...

A new vaccine targeting Streptococcus suis—a severe bacterial infection impacting UK pigs—is anticipated to be a ‘game-changer’ for the industry. Created through a collaboration among Moredun ...

Terns Pharmaceuticals has announced a $125 million stock offering, following the release of promising Phase I data for TERN-601, their oral candidate aimed at obesity. This significant move positions ...

Sunstar Oral Health, part of Sunstar, in partnership with the European Dental Hygienist Federation (EDHF) has announced the 2024 winners of the European Award of Distinction for Dental Hygienists. The ...

In phase 3 trials, GSK’s long-acting asthma medication, depemokimab, showed encouraging results, reducing the frequency of asthma attacks in individuals with severe asthma and type 2 inflammation.

In a significant breakthrough for the life sciences industry, Pfizer and Valneva have announced encouraging results for their Lyme disease vaccine candidates. The phase 2 trials demonstrated strong ...

On September 4, 2024, Defra announced the approval of three vaccines to address the bluetongue outbreak currently affecting eastern England. The vaccines, Bluevac-3, Bultavo-3, and Syvazul BTV3, have ...